Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267046
Status:
COMPLETED
Last Update Posted:
2012-05-16
First Post:
2005-12-19
Brief Title:
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Phase II Study to Evaluate the Pharmacokinetics Safety and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary
1 To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis OM in patients with sarcoma receiving multicycle chemotherapy
2 To evaluate the pharmacokinetics PK of palifermin when given pre chemotherapy
3 To evaluate the safety profile of palifermin when combined with multicycle chemotherapy
Exploratory
1 To evaluate the biologic effect of palifermin on oral mucosa
2 To investigate potential biomarker development by biochemical analysis in blood cells serum and plasma
3 To investigate the effects of genetic variation in mucositis genes drug metabolism genes and drug target genes on patient response to the treatment regimen
1 To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis OM in patients with sarcoma receiving multicycle chemotherapy
2 To evaluate the pharmacokinetics PK of palifermin when given pre chemotherapy
3 To evaluate the safety profile of palifermin when combined with multicycle chemotherapy
Exploratory
1 To evaluate the biologic effect of palifermin on oral mucosa
2 To investigate potential biomarker development by biochemical analysis in blood cells serum and plasma
3 To investigate the effects of genetic variation in mucositis genes drug metabolism genes and drug target genes on patient response to the treatment regimen
Detailed Description:
Palifermin is similar to a protein keratinocyte growth factor KGF that is naturally made in your body in small amounts The function of palifermin is to stimulate the growth of specific cells that form the tissue lining of your mouth and digestive tract Damage to these cells results in the breakdown of the normal protective barrier that these cells usually provide potentially resulting in infection
If you are eligible to take part in this study you will be randomly assigned as in the toss of a coin to receive either palifermin or placebo by vein 3 days before each cycle of chemotherapy This will be done for 18 weeks a total of 12 injections A placebo is a substance that looks like the study drug but which has no active ingredients The infusion time will last 15-30 seconds At the beginning of the study for every 3 patients who are enrolled on this study 2 of the 3 will receive palifermin Neither you nor the study doctor will know which study drug you are assigned to receive
Within 1 or 2 days before you receive your first dose of palifermin and between 48 to 72 hours after you receive your first dose of palifermin additional non-invasive optical imaging procedures may be performed The purpose of these imaging procedures is to evaluate the effects of palifermin on mucosa mucosal thickness The types of optical imaging that may be done include optical coherence tomography OCT fluorescence and reflectance spectroscopy or confocal microscopy The oral cavity will be inspected and photographed A probe about the size of a pen will be placed on one or two sites of oral buccal mucosa A beam of light will then be directed to the oral tissue and optical signals will be collected from each site This will take about 1 minute for each site Before using the probe for each new participant it will be disinfected per standard practice
You will receive adriamycin with ifosfamide or cisplatin chemotherapy Adriamycin will be given as a continuous infusion through your central venous catheter CVC for 3 days Ifosfamide will be given intravenously intravenously IV--through a needle in your vein through your CVC over 3 hours every day for 4 days Mesna will be given as a 24-hour IV infusion through your CVC every day for 4 days through the same catheter Mesna is used to protect against bladder-related side effects For patients with certain types of sarcoma vincristine will be given through the catheter by rapid infusion on Day 1 only In patients with bone sarcoma cisplatin will be given on the first day as IV or intra-arterial infusion over around 4 hours instead of ifosfamide
You will need to come in to M D Anderson every 3 weeks for about 4 to 5 months during the treatment period unless your doctor decides you need to come in more frequently At these visits you will have your vital signs measured and routine blood tests about 3 teaspoons each will be performed In addition you may have your oral cavity examined and photographed before and after receiving the study drug Every effort will be made to take photographs in which you cannot be identified
Additional blood samples about 3 teaspoons will be taken before each cycle and as frequently as needed to measure your blood count and other tests to monitor the drug side effects and treatment effects By the end of the study you will have given about 10 tablespoons of blood This amount includes the optional blood draws should you choose to allow it to be drawn
You will be responsible for notifying study staff at your doctors visits or over the phone with the study staff of any side effects you experience or medications over the counter or prescription that you take during the treatment period You will also be required to notify any other doctors separate from the study doctors you see that you are participating in this research study
If your anemia becomes severe while you are on study then a transfusion may be recommended If mucositis develops the prohibited medicines can be allowed for treatment of the condition If you experience an intolerable side effect while on study you may be taken off study If you leave the study early for any reason your doctor will continue to follow your progress for 4 weeks and will access your medical records for a minimum of 1 year after the last dose of study drug either palifermin or placebo was given
At your end of study visit you will be evaluated for your disease status with imaging studies computed tomography CT scans or magnetic resonance images MRI and your weight and vitals signs will be measured You will report any medications you have taken since your last visit and any side effects or blood transfusion that you have had You will also have a final blood draw about 3 teaspoons for routine tests
The total length of your involvement in this study is expected to be about 18 weeks 4 to 5 months
If you are eligible to take part in this study you will be randomly assigned as in the toss of a coin to receive either palifermin or placebo by vein 3 days before each cycle of chemotherapy This will be done for 18 weeks a total of 12 injections A placebo is a substance that looks like the study drug but which has no active ingredients The infusion time will last 15-30 seconds At the beginning of the study for every 3 patients who are enrolled on this study 2 of the 3 will receive palifermin Neither you nor the study doctor will know which study drug you are assigned to receive
Within 1 or 2 days before you receive your first dose of palifermin and between 48 to 72 hours after you receive your first dose of palifermin additional non-invasive optical imaging procedures may be performed The purpose of these imaging procedures is to evaluate the effects of palifermin on mucosa mucosal thickness The types of optical imaging that may be done include optical coherence tomography OCT fluorescence and reflectance spectroscopy or confocal microscopy The oral cavity will be inspected and photographed A probe about the size of a pen will be placed on one or two sites of oral buccal mucosa A beam of light will then be directed to the oral tissue and optical signals will be collected from each site This will take about 1 minute for each site Before using the probe for each new participant it will be disinfected per standard practice
You will receive adriamycin with ifosfamide or cisplatin chemotherapy Adriamycin will be given as a continuous infusion through your central venous catheter CVC for 3 days Ifosfamide will be given intravenously intravenously IV--through a needle in your vein through your CVC over 3 hours every day for 4 days Mesna will be given as a 24-hour IV infusion through your CVC every day for 4 days through the same catheter Mesna is used to protect against bladder-related side effects For patients with certain types of sarcoma vincristine will be given through the catheter by rapid infusion on Day 1 only In patients with bone sarcoma cisplatin will be given on the first day as IV or intra-arterial infusion over around 4 hours instead of ifosfamide
You will need to come in to M D Anderson every 3 weeks for about 4 to 5 months during the treatment period unless your doctor decides you need to come in more frequently At these visits you will have your vital signs measured and routine blood tests about 3 teaspoons each will be performed In addition you may have your oral cavity examined and photographed before and after receiving the study drug Every effort will be made to take photographs in which you cannot be identified
Additional blood samples about 3 teaspoons will be taken before each cycle and as frequently as needed to measure your blood count and other tests to monitor the drug side effects and treatment effects By the end of the study you will have given about 10 tablespoons of blood This amount includes the optional blood draws should you choose to allow it to be drawn
You will be responsible for notifying study staff at your doctors visits or over the phone with the study staff of any side effects you experience or medications over the counter or prescription that you take during the treatment period You will also be required to notify any other doctors separate from the study doctors you see that you are participating in this research study
If your anemia becomes severe while you are on study then a transfusion may be recommended If mucositis develops the prohibited medicines can be allowed for treatment of the condition If you experience an intolerable side effect while on study you may be taken off study If you leave the study early for any reason your doctor will continue to follow your progress for 4 weeks and will access your medical records for a minimum of 1 year after the last dose of study drug either palifermin or placebo was given
At your end of study visit you will be evaluated for your disease status with imaging studies computed tomography CT scans or magnetic resonance images MRI and your weight and vitals signs will be measured You will report any medications you have taken since your last visit and any side effects or blood transfusion that you have had You will also have a final blood draw about 3 teaspoons for routine tests
The total length of your involvement in this study is expected to be about 18 weeks 4 to 5 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None